Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
@article{Zhang2020SafetyTA, title={Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial}, author={Y. Zhang and G. Zeng and H. Pan and Changgui Li and Ya-ling Hu and Kai Chu and W. Han and Zhen Chen and Rong Tang and Weidong Yin and X. Chen and Yuansheng Hu and X. Liu and Congbing Jiang and J. Li and Minnan Yang and Y. Song and X. Wang and Qiang Gao and F. Zhu}, journal={The Lancet. Infectious Diseases}, year={2020}, volume={21}, pages={181 - 192} }
Background
With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19, containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for its safety, tolerability and immunogenicity.
Methods
In this randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, healthy… CONTINUE READING
13 Citations
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- Medicine
- The New England journal of medicine
- 2020
- 108
Immune response scenario and vaccine development for SARS-CoV-2 infection
- Medicine
- International Immunopharmacology
- 2021
Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials
- Medicine
- Vaccines
- 2020
- PDF
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
- Medicine
- Advanced Drug Delivery Reviews
- 2021
- 1
Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines
- Medicine
- Biomedicine & Pharmacotherapy
- 2021
The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic
- Medicine
- International journal of molecular sciences
- 2020
- 1
- Highly Influenced
- PDF
An update to “novel therapeutic approaches for treatment of COVID-19”
- Medicine
- Journal of molecular medicine
- 2021
- PDF
Development and deployment of COVID-19 vaccines for those most vulnerable
- Medicine
- Science Translational Medicine
- 2021
- 1
Site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells
- Biology, Medicine
- bioRxiv : the preprint server for biology
- 2021
References
SHOWING 1-10 OF 32 REFERENCES
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- Medicine
- The Lancet Infectious Diseases
- 2020
- 33
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- Medicine
- The Lancet
- 2020
- 358
- PDF
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
- Medicine
- JAMA
- 2020
- 91
- PDF
Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial.
- Medicine
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
- 2019
- 3
Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial.
- Medicine
- Vaccine
- 2012
- 88
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- Medicine
- The New England journal of medicine
- 2020
- 503
- PDF
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity
- Medicine
- Nature communications
- 2020
- 102
- PDF
Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients
- Medicine
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- 2020
- 31